4.7 Article

LC-MS/MS Method for the Quantification of PARP Inhibitors Olaparib, Rucaparib and Niraparib in Human Plasma and Dried Blood Spot: Development, Validation and Clinical Validation for Therapeutic Drug Monitoring

Journal

PHARMACEUTICS
Volume 15, Issue 5, Pages -

Publisher

MDPI
DOI: 10.3390/pharmaceutics15051524

Keywords

LC-MS/MS; PARP inhibitors; olaparib; rucaparib; niraparib; human plasma; dried blood spot; therapeutic drug monitoring

Ask authors/readers for more resources

Poly (ADP-ribose) polymerase inhibitors (PARPis) are increasingly important in oncology, and their therapeutic drug monitoring (TDM) could benefit patients. This study developed and validated a liquid chromatography-tandem mass spectrometry method for quantifying olaparib, rucaparib, and niraparib in both human plasma and dried blood spot (DBS). The correlation between drug concentrations measured in these two matrices was assessed. Results showed a strong correlation between plasma and DBS for olaparib and niraparib, though further data is needed to establish a robust regression analysis for rucaparib. The study provides a solid foundation for the feasibility of using both plasma and DBS matrices for PARPis TDM.
Poly (ADP-ribose) polymerase inhibitors (PARPis) are becoming increasingly meaningful in oncology, and their therapeutic drug monitoring (TDM) might be beneficial for patients. Several bioanalytical methods have been reported for PARPis quantification in human plasma, but advantages might be obtained using dried blood spot (DBS) as a sampling technique. Our aim was to develop and validate a liquid chromatography-tandem mass spectrometric (LC-MS/MS) method for olaparib, rucaparib, and niraparib quantification in both human plasma and DBS matrices. Additionally, we aimed to assess the correlation between the drug concentrations measured in these two matrices. DBS from patients was obtained using Hemaxis DB10 for volumetric sampling. Analytes were separated on a Cortecs-T3 column and detected with electrospray ionization (ESI)-MS in positive ionization mode. Validation was performed according to the latest regulatory guidelines, in the range (ng/mL) 140-7000 for olaparib, 100-5000 for rucaparib, and 60-3000 for niraparib, within the hematocrit (Hct) range 29-45%. The Passing-Bablok and Bland-Altman statistical analyses revealed a strong correlation between plasma and DBS for olaparib and niraparib. However, due to the limited amount of data, it was challenging to establish a robust regression analysis for rucaparib. To ensure a more reliable assessment, additional samples are required. The DBS-to-plasma ratio was used as a conversion factor (CF) without considering any patient-related hematological parameters. These results provide a solid basis for the feasibility of PARPis TDM using both plasma and DBS matrices.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available